Document is current
Any future updates will be listed below
-
Authors
Pasnoor, Mamatha https://orcid.org/0000-0001-7424-4719
Miller-Wilson, Lesley-Ann
Edwards, Yuriy
Copley-Merriman, Kati
Costello, Jessica
Foss, Allison
Muppidi, Srikanth
-
Funding
Funding for this research was provided by:
Immunovant, Inc.
- License Information
-
More Information
Article History
Received: 8 October 2025
Revised: 26 January 2026
Accepted: 27 January 2026
First Online: 25 April 2026
Declarations
:
: Mamatha Pasnoor has served on advisory board meetings and as a consultant for Immunovant, Amgen, CSL Behring, Grifols, argenx, Annexon, Janssen, Johnson and Johnson, Catalyst, UCB. Kati Copley-Merriman and Jessica Costello are employees of RTI Health Solutions. Allison Foss has served as a representative on the Leadership Council for argenx and for the Rare Disease Connect in Neurology (RDCN) learning program led by UCB, and as a participant for the Regeneron Patient Council; she has also received compensation for speaking engagements with Amgen, Cartesian Therapeutics and Immunovant, Inc. Lesley-Ann Miller-Wilson and Yuriy Edwards are employees of Immunovant, Inc. Srikanth Muppidi has served on advisory board meetings for Alexion, AstraZeneca Rare Disease, argenx, Horizon Therapeutics, and Ra Pharmaceuticals (now UCB).
